COGT Stock Risk & Deep Value Analysis
Cogent Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About COGT Stock
We analyzed Cogent Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran COGT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is COGT Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for COGT?
- ⚠
Negative or mixed clinical trial results (APEX Part 2)
- ⚠
Regulatory delays or outright rejection of Bezucclastinib
- ⚠
Emergence of a superior competitive therapy for SM
- ⚠
Unexpected safety signals in ongoing trials
Unlock COGT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Cogent Biosciences Inc (COGT) Do?
Market Cap
$4.67B
Sector
Healthcare
Industry
Biotechnology
Employees
205
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Visit Cogent Biosciences Inc WebsiteIs COGT Stock Undervalued?
Unlock the full AI analysis for COGT
Get the complete DVR score, risk analysis, and more
Does COGT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property around Bezucclastinib and its unique mechanism of action, reinforced by robust clinical data. Durability will depend on successful patent defense and the ongoing demonstration of its superior profile relative to competitors in real-world settings.
Moat Erosion Risks
- •Patent expiration or challenge before peak sales are achieved
- •Development of a more effective or safer competitor molecule
- •Failure to achieve broad market adoption post-approval
COGT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive COGT Stock Higher?
Near-Term (0-6 months)
- •Updated data from APEX Part 2 (Non-Advanced SM) clinical trial (Q2 2026)
- •Presentation of additional clinical data at major medical conferences (e.g., EHA, ASH 2026)
- •Potential initiation of registrational trial for additional indications
Medium-Term (6-18 months)
- •Potential NDA/MAA filing for Bezucclastinib in Non-Advanced SM (Late 2026 / Early 2027)
- •Strategic partnership or licensing agreements for ex-US territories
- •Expansion of pipeline assets into new disease areas
Long-Term (18+ months)
- •FDA/EMA approval and commercial launch of Bezucclastinib in Non-Advanced SM (2027-2028)
- •Establishment of Bezucclastinib as the market leader in SM
- •Label expansion into additional mast cell-driven diseases
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for COGT?
- ✓
Positive clinical data readouts (especially APEX Part 2)
- ✓
Progress in regulatory interactions and filing timelines
- ✓
Any signs of competitive pressure from other SM therapies
- ✓
Cash runway updates and financing activities
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for COGT (Cogent Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
